Table 3.
Mutation frequencies in 68 GCAs (this study) compared to UEAs, PAs and IGAs.#
| Gene | GCA (n=68) | UEA (n=21) | PA (n=178) | IGA (n=148) |
|---|---|---|---|---|
| TP53 | 41% | 5%** | 56%* | 57%* |
| CDKN2A | 18% | 0%* | 19% | 1%** |
| KRAS | 18% | 11% | 62%** | 6%* |
| STK11 | 10% | 0% | 2%** | 1%** |
| ERBB3 | 10% | 14% | 1%** | 5% |
| GNAS | 9% | 5% | 5% | 3% |
| ERBB2 | 9% | 18% | 1%** | 3% |
| SMAD4 | 9% | 0% | 19%* | 7% |
| PIK3CA | 7% | 25%* | 3% | 11% |
| ARID1A | 6% | 10% | 5% | 14% |
*
p<0.05,
**
p<0.01,
Fisher’s exact test (two-tailed, comparing mutation frequencies in GCA with those in each of the other cancer types).
GCA = gastric-type cervical adenocarcinoma; UEA = usual-type (HPV-associated) endocervical adenocarcinoma; PA = pancreatic adenocarcinoma; IGA = intestinal/tubular gastric adenocarcinoma